Clinical Trial

CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. The study will enroll patients who have completed two cycles of induction chemotherapy and have not achieved a partial or complete response. Participants will receive one of the two treatment options to evaluate their three-year progression-free survival (PFS) and other clinical outcomes.
Trial Details
NCT Number NCT07399158
Lead Sponsor Fujian Cancer Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 223 participants
Start Date 2026-02-01
Primary Completion 2027-01-31 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-10